Loading chat...

MD HB572

Bill

Official Source

Status

Introduced

1/23/2025

Primary Sponsor

Nicholaus Kipke

Click for details

Origin

House of Delegates

2025 Regular Session

AI Summary

  • Licensed health care providers issuing standing orders for opioid overdose reversal drugs must allow individuals to choose any formulation of any FDA-approved reversal drug
  • Authorized private and public entities that prescribe and dispense overdose reversal drugs are not required to stock or dispense all FDA-approved formulations
  • "Private or public entity" includes health care providers, local health departments, community-based organizations, substance abuse treatment organizations, and others addressing drug addiction
  • Effective date: October 1, 2025

Legislative Description

Public Health - Opioid Overdose Reversal Drugs

Licenses

Last Action

Withdrawn by Sponsor

3/15/2025

Committee Referrals

Health and Government Operations1/23/2025

Full Bill Text

No bill text available